Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

17.55
+0.55003.24%
Post-market: 17.700.1500+0.85%19:58 EDT
Volume:4.28M
Turnover:74.94M
Market Cap:14.00B
PE:-15.70
High:17.70
Open:17.20
Low:17.14
Close:17.00
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.56
T/O Rate:2.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:22.22
PE(LYR):-12.15

Loading ...

Summit Therapeutics co-CEO Robert W. Duggan acquires 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics Withdraws Public Offering Due to Market Conditions

MT Newswires Live
·
Jun 11

Summit Therapeutics withdraws proposed underwritten public offering

TIPRANKS
·
Jun 11

BUZZ-Summit Therapeutics rebounds after pulling stock offering

Reuters
·
Jun 11

BRIEF-Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing

Reuters
·
Jun 11

Summit Therapeutics - No Securities to Be Sold in Proposed Underwritten Public Offering - SEC Filing

THOMSON REUTERS
·
Jun 11

Summit Therapeutics Stock Slides to 52-Week Low on Plans for Secondary Offering

Dow Jones
·
Jun 11

Summit Therapeutics falls -10.2%

TIPRANKS
·
Jun 11

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jun 10

BRIEF-Summit Therapeutics Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 10

Summit Therapeutics launches USD 500 million common stock offering

Reuters
·
Jun 10

Summit Therapeutics - Commences $500 Mln Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
Jun 10

Summit Therapeutics - Proceeds to Fund Ivonescimab R&D, Working Capital, and General Corporate Purposes

THOMSON REUTERS
·
Jun 10

Summit Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Jun 10

Summit Therapeutics: Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Jun 10

Summit Therapeutics (SMMT) Is Down 6.0% After New Ivonescimab ASCO Data - Has The Bull Case Changed?

Simply Wall St.
·
Jun 08

The Era of the One-Size-Fits-All Cancer Drug Is Ending -- Heard on the Street -- WSJ

Dow Jones
·
Jun 06

Summit Therapeutics Co-CEO Robert W. Duggan reports purchase of 100,000 common shares for $1.46 million

Reuters
·
Jun 05

Summit Therapeutics Co-CEO Mahkam Zanganeh acquires $1.46 million in common shares

Reuters
·
Jun 05

Summit Therapeutics COO/CFO Manmeet Soni acquires 50,000 common shares worth $722,250

Reuters
·
Jun 05